Cancer Dx Firm Cernostics Raises $1.4M | GenomeWeb

NEW YORK (GenomeWeb News) – Cancer diagnostics and prognostics firm Cernostics recently announced it raised $1.4 million in a Series B financing round.

The funds will be used to further develop and commercialize the Pittsburgh-based company's lead product called TissueCypher:Barrett's. Its technology, Cernostics said, quantifies whole slide digital images, providing more information and accuracy than traditional subjective tissue diagnostics and will help eliminate uncertainty around treatment for Barrett's esophagus.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.